Anti-Mouse/Human TYRP1/TRP1 (Clone TA99) – Purified No Carrier Protein

Anti-Mouse/Human TYRP1/TRP1 (Clone TA99) – Purified No Carrier Protein

Product No.: T747

- -
- -
Clone
TA-99
Target
TYRP1/TRP1 (gp75)
Formats AvailableView All
Product Type
Hybridoma Monoclonal Antibody
Alternate Names
CAS2, CATB, GP75, OCA3, TRP, 5,6-dihydroxyindole-2-carboxylic acid oxidase, TRP1, TRP-1, catalase B, DHICA oxidase, glycoprotein 75, melanoma antigen gp75, MEL-5
Isotype
Mouse IgG2a k
Applications
ELISA
,
FA
,
ICC
,
IF Microscopy
,
IHC
,
in vivo
,
IP
,
RIA

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Host Species
Mouse
Immunogen
SK-MEL-23 Melanoma cell line
Product Concentration
≥1.0 mg/ml
Purity
≥90% monomer by analytical SEC
Formulation
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.
State of Matter
Liquid
Product Preparation
Purified antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Regulatory Status
Research Use Only
Country of Origin
USA
Shipping
2 – 8° C Wet Ice
Additional Applications Reported In Literature ?
ELISA,
FA,
ICC,
IF microscopy,
IHC,
in vivo,
IP,
RIA
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
TA99 activity is directed against tyrosinase-related protein 1 (TYRP1/TRP1), a 75kDa differentiation-related human glycoprotein (gp75), formerly referred to as pigmentation- associated antigen (PAA).
Background
The pigment melanin is produced by specialized organelles called melanosomes that are present in melanocytes1. Melanosomes mature through four morphologically distinct stages, and it is in Stage II that melanin synthesis and deposition is initiated by enzymes including TYRP12.TYRP1/TRP1 (gp75) is a 75 kDa melanosomal membrane protein3,4 involved in melanin synthesis that is also the most abundant glycoprotein synthesized by pigmented melanocytes and melanomas5. In mice, TYRP1/TRP1 (gp75) is also known as the b (brown) locus and determines coat color6. Gene identity is 88% conserved between mouse and human. TYRP1/TRP1 (gp75) is glycosylated by addition and processing of five or more Asn-linked carbohydrate chains.

TA99 was generated by immunizing mice with whole cells of a darkly pigmented melanoma (SK-MEL-23) and fusing spleen cells with NS-1 cells for hybridoma production4. TA99 is reactive against mature melanosomes1. In normal tissues, TA99 reacts with elanin-containing cells in the basal layer of the epidermis as well as pigmented cells of the eye4. TA99 is widely used as a melanosomal marker.

The benefits of TA99 in cancer therapy are being investigated. In mouse, TA99 prevents outgrowth of B16F10 melanoma metastases5,7. In humans, TA99 is used for melanoma diagnosis5. Additionally, TA99 can target subcutaneous human melanoma xenografts in vivo5 and can induce neutrophil recruitment in tumor sites in a B16 melanoma mouse model8. TA99 also improves DNA vaccination against melanoma antigen gp1009. FcγR signaling is required for TA99 action5,9,10,11. TA99 has no impact on tumor outgrowth in established solid tumors12.

Antigen Distribution
TYRP1/TRP1 (gp75) is expressed by pigmented melanoma cells and cultured melanocytes. It predominantly localizes with melanosomes but can also be expressed on the cell surface. It is strongly expressed in B16F10 melanoma cells in vivo.
NCBI Gene Bank ID
UniProt.org
Research Area
Cancer

References & Citations

1 Thomson TM, Real FX, Murakami S, et al. J Invest Dermatol. 90(4):459-466. 1988.
2 Sitaram A, Marks MS. Physiology (Bethesda). 27(2):85-99. 2012.
3 Vijayasaradhi S, Doskoch PM, Houghton AN. Exp Cell Res. 196(2):233-240. 1991.
4 Thomson TM, Mattes MJ, Roux L, et al. J Invest Dermatol. 85(2):169-174. 1985.
5 Boross P, Jansen JH, van Tetering G, et al. Immunol Lett. 160(2):151-157. 2014.
6 Vijayasaradhi S, Houghton AN. Int J Cancer. 47(2):298-303. 1991.
7 Otten MA, van der Bij GJ, Verbeek SJ, et al. J Immunol. 181(10):6829-6836. 2008.
8 Chu D, Zhao Q, Yu J, et al. Adv Healthc Mater. 5(9):1088-1093. 2016.
9 Saenger YM, Li Y, Chiou KC, et al. Cancer Res. 68(23):9884-9891. 2008.
10 Murer P, Kiefer JD, Plüss L, et al. J Invest Dermatol. 139(6):1339-1348. 2019.
11 Bevaart L, Jansen MJ, van Vugt MJ, et al. Cancer Res. 66(3):1261-1264. 2006.
12 Benonisson H, Sow HS, Breukel C, et al. J Immunol. 201(12):3741-3749. 2018.
13 Vijayasaradhi S, Bouchard B, Houghton AN. J Exp Med. 171(4):1375-1380. 1990.
14 Bouchard B, Fuller BB, Vijayasaradhi S, et al. J Exp Med. 169(6):2029-2042. 1989.
15 Cui J, Arita Y, Bystryn JC. Pigment Cell Res. 8(1):53-59. 1995.
16 Kemp EH, Waterman EA, Gawkrodger DJ, et al. Br J Dermatol. 139(5):798-805. 1998.
17 Bin BH, Bhin J, Yang SH, et al. PLoS One. 9(8):e105965. 2014.
18 van Spriel AB, van Ojik HH, Bakker A, et al. Blood. 101(1):253-258. 2003.
19 Patel D, Bassi R, Hooper AT, et al. Anticancer Res. 28(5A):2679-2686. 2008.
20 Ly LV, Sluijter M, van der Burg SH, et al. J Immunol. 190(1):489-496. 2013.
21 They L, Michaud HA, Becquart O, et al. Oncoimmunology. 6(10):e1353857. 2017.
22 Pérez-Lorenzo R, Erjavec SO, Christiano AM, et al. Oncotarget. 12(2):66-80. 2021.
23 Tursi NJ, Xu Z, Helble M, et al. Front Immunol. 14:1072810. 2023.
24 Palmeri JR, Lax BM, Peters JM, et al. Nat Commun. 15(1):1900. 2024.
25 Albanesi M, Mancardi DA, Macdonald LE, et al. J Immunol. 189(12):5513-5517. 2012.
26 Dippel E, Haas N, Grabbe J, et al. Br J Dermatol. 132(2):182-189. 1995.
27 Dean NR, Brennan J, Haynes J, et al. Appl Immunohistochem Mol Morphol. 10(3):199-204. 2002.
28 Welt S, Mattes MJ, Grando R, et al. Proc Natl Acad Sci U S A. 84(12):4200-4204. 1987.
29 Zhao H, Eling DJ, Medrano EE, et al. J Invest Dermatol. 106(4):744-752. 1996.
Indirect Elisa Protocol
FA
ICC
IF Microscopy
IHC
in vivo Protocol
Immunoprecipitation Protocol
RIA

Certificate of Analysis

Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.